Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2025	Mar. 31, 2024
Revenue		$ 113,243	$ 101,132	$ 330,962	$ 312,262
Total cost of revenue	[1]	81,616	72,058	222,974	207,793
Research and development	[2]	10,712	10,909	36,472	40,203
Products
Revenue	[3]	57,320	49,603	166,878	154,491
Total cost of revenue		44,301	35,945	111,315	105,977
Services
Revenue	[4]	55,923	51,529	164,084	157,771
Total cost of revenue		37,315	36,113	111,659	101,816
Revenue from Joint Venture
Total cost of revenue		17,411	13,887	53,303	40,260
Research and development		373	0	1,105	199
Revenue from Joint Venture | Products
Revenue		17,967	15,662	76,333	55,504
Revenue from Joint Venture | Services
Revenue		$ 5,351	$ 3,982	$ 14,588	$ 10,970

[1] Includes cost of revenue from sales to the joint venture, an equity method investment, of $17,411 and $53,303 during the three and nine months ended March 31, 2025, and $13,887 and $40,260 during the three and nine months ended March 31, 2024, respectively.

[2] Includes charge backs to the joint venture, an equity method investment, related to research and development of $373 and $1,105 during the three and nine months ended March 31, 2025, and $199 during the nine months ended March 31, 2024. There were no charge backs to the joint venture related to research and development during the three months ended March 31, 2024.

[3] Includes sales of products to the joint venture, an equity method investment, of $17,967 and $76,333 during the three and nine months ended March 31, 2025, and $15,662 and $55,504 during the three and nine months ended March 31, 2024, respectively. See Note 12.

[4] Includes sales of services to the joint venture, an equity method investment, of $5,351 and $14,588 during the three and nine months ended March 31, 2025, and $3,982 and $10,970 during the three and nine months ended March 31, 2024, respectively. See Note 12.